The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adrian Vella
• Collaborators: National Center for Research Resources (NCRR); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Gastric Inhibitory Polypeptide; Hormones; Incretins

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of > 110 mg/dL

• Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).

Exclusion Criteria:

• Subjects taking thiazolidinediones

• Subjects with active systemic illness

• Subjects with active microvascular or macrovascular complications of their diabetes

• For female subject: positive pregnancy test at the time of enrollment in study